Type A viral hepatitis: Epidemiology, diagnosis, and prevention

Clinical Chemistry

Volumn 43, Issue 8 SUPPL., 1997, Pages 1494-1499

  Lemon, Stanley M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE;

AGE DISTRIBUTION; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE COURSE; HEPATITIS A; HUMAN; INFECTION PREVENTION; INFECTION RISK; RISK FACTOR; RISK MANAGEMENT; VACCINATION; VIRUS TRANSMISSION;

HEPATITIS A VIRUS;

EID: 0030797126     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/43.8.1494     Document Type: Conference Paper

References (15)

1. Hadler SC. Global impact of hepatitis A infection: changing patterns. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991:14-9.
2. Lemon SM, Shapiro CN. The value of immunization against hepatitis A. Infect Agents Dis 1994;3:38-49.
3. Lemon SM. HAV: current concepts of the molecular virology, immunobiology and approaches to vaccine development. Rev Med Virol 1992;2:73-87.
4. Robertson BH, Lemon SM. Hepatitis A and E viruses. In: Collier L, ed. Topley and Wilson's microbiology and microbial infections, 9th ed. London: Edward Arnold, in press.
5. Francis DP, Hadler SC, Prendergast TJ, Peterson E, Ginsberg MM, Lookabaugh C, et al. Occurrence of hepatitis A, B, and non-A/ non-B in the United States. CDC sentinel county hepatitis study I. Am J Med 1984;76:69-74.
6. Hadler SC, Webster HM, Erben JJ, Swanson JE, Maynard JE. Hepatitis A in day-care centers. A community-wide assessment. N Engl J Med 1980;302:1222-7.
7. Widell A, Hansson BG, Moestrup T, Nordenfelt E. Increased occurrence of hepatitis A with cyclic outbreaks among drug addicts in a Swedish community. Infection 1983;11:198-200.
8. Lemon SM, Binn LN, Marchwicki R, Murphy PC, Ping LH, Jansen RW, et al. In vivo replication and reversion to wild type of a neutralization-resistant antigenic variant of hepatitis A virus. J Infect Dis 1990;161:7-13.
9. Vallbracht A, Maier K, Stierhof YD, Wiedmann KH, Flehmig B, Fleischer B. Liver-derived cytotoxic T cells in hepatitis A virus infection. J Infect Dis 1989;160:209-17.
10. Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985;122:226-33.
11. Lemon SM, Binn LN. Serum neutralizing antibody response to hepatitis A virus. J Infect Dis 1983;148:1033-9.
12. Lemon SM, Murphy PC, Provost P, et al. Immunoprecipitation and virus neutralization assays demonstrate qualitative differences in the protective antibody responses to an inactivated hepatitis A vaccine and passive immunization with immune globulin. J Infect Dis, in press.
13. Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992;327:453-7.
14. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:1328-34.
15. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997;336:196-204.